Gene therapy trial for cystic fibrosis halted early

NCT ID NCT06515002

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a single dose of an inhaled gene therapy called BI 3720931 in adults with cystic fibrosis who cannot take standard CFTR modulator drugs. The trial was in two phases and included only 5 participants. It was terminated early, so we do not have full results on safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3720931 (inhaled gene therapy)
What this could lead to: If it works, this could provide a new treatment option for people with cystic fibrosis who cannot take current modulator drugs.
What could go wrong: This was a very early, small trial (only 5 participants) and was terminated, so results are limited. Gene therapies can have unexpected side effects and may not improve lung function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hôpital Gui de Chauliac

Montpellier, 34295, France
Osp. Pediatrico Bambin Gesù

Roma, 00165, Italy
Royal Brompton Hospital

London, SW3 6JY, United Kingdom
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.